CagriSema 2.4mg

CagriSema is a fixed-dose combination therapy of 2.4mg semaglutide with 2.4mg cagrilintide, in obesity patients. Cagrilintide is a long-acting amylin analogue potentiating semaglutide’s weight loss effects.